Search

everythinglearnresearchcommunity

for

Search:↓

CB-03-01 (Breezula) powder for hair loss. Users discuss its availability and seek feedback on its effectiveness.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

Ketoconazole is no longer sold in the UK, and pharmacies have replaced it with non-ketoconazole options. Users are discussing its availability and possible alternatives.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It highlights a study suggesting that sulforaphane may reduce DHT levels and promote hair growth in mice.

JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.

RU58841 was the only treatment that slowed hair loss and reduced irritation for a DUPA sufferer after trying finasteride, minoxidil, and dutasteride with no success. The user continues using 6mg oral minoxidil, 0.5mg dutasteride, and an 8% RU58841 solution.

Switching from spironolactone to bicalutamide caused severe hair shedding, despite using treatments like dutasteride, minoxidil, and estradiol injections. The user is experiencing androgenetic alopecia and is seeking solutions to stop the hair loss.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

The user has been using finasteride and minoxidil for hair loss but experienced worsening temple recession. They suspect they might be more sensitive to testosterone and are considering trying RU58841 or CB 03 01 as additional treatments.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.

Alfatradiol is discussed as a weak 5ARI and estrogen, not as effective as minoxidil, RU58841, or CB-03-01, but a safe alternative for those who can't use finasteride. Users express frustration over the lack of strong FDA-approved topical antiandrogens for hair loss.

A user experienced reduced stress and improved hair appearance after getting a buzzcut while using finasteride, minoxidil, and microneedling. The user feels the haircut and treatments may have improved hair quality and filled in patchy areas.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

A user is seeing good results with RU58841 for hair loss, noting reduced shedding and thicker hair. They plan to use pumpkin seed oil as a solvent to avoid water content, which they believe reduces the effectiveness of anti-androgens.

The conversation discusses whether to use finasteride for hair loss, considering its role in inhibiting DHT and 5AR, which can affect brain function and mood. Some users report anxiety and depression from finasteride, while others do not experience these side effects and emphasize the importance of DHT for brain and prostate health.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

A 32-year-old male shares his 5-year progress using finasteride, minoxidil, RU58841, and ketoconazole for hair loss. Despite consistent use, he feels his hair isn't as thick as before and is concerned about continued shedding and hairline miniaturization.

The Shiseido/Replicel RCH-01 trial results were disappointing and ineffective. Users expressed skepticism and frustration, suggesting alternatives like Tsuji or simply accepting baldness.

Treatments for hair loss, including Minoxidil, finasteride, and RU58841. The post discusses the potential benefits of Pyrilutamide compared to RU58841 in terms of strength and longevity.

The user is experiencing ongoing hair loss despite using a comprehensive treatment regimen including dutasteride, oral minoxidil, cyproterone acetate, transdermal estradiol, and topical bicalutamide. They suspect cyproterone acetate may be worsening their hair loss and are considering switching to injection monotherapy.

PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hair follicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.

The conversation discusses using topical cetirizine as a treatment for androgenetic alopecia (hair loss). Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The user experienced severe hair shedding despite using oral finasteride, minoxidil, dutasteride, and RU58841, and was diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD). They are considering switching to topical treatments due to the ineffectiveness of their current regimen.

A female user is considering using RU58841 with minoxidil 2.5% to reduce side effects like facial hair from minoxidil 5%, while also using copper peptides and a hair serum. Other users discuss alternative treatments like spironolactone, alfatradiol, and the side effects of finasteride.

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

CBD may increase hair counts slightly, but results are minimal without additional treatments like minoxidil or finasteride. Some users suggest combining CBD with other methods for better results.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

The conversation discusses switching from RU58841 to pyrilutamide for hair loss treatment, with users generally recommending staying on RU58841 if it is effective. RU58841 is sourced from GeneTherica, which ships worldwide.

Reducing the dose of Pyrilutamide from 5mg to 2.5mg may still maintain hair loss results, but effectiveness can vary. Users discuss the cost and dosage implications, with some cautioning against reducing the dose due to its dose-dependent nature.